Septerna (NASDAQ:SEPN) Shares Gap Up – Should You Buy?

Shares of Septerna, Inc. (NASDAQ:SEPN) gapped up prior to trading on Wednesday . The stock had previously closed at $14.54, but opened at $15.34. Septerna shares last traded at $14.57, with a volume of 10,601 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on SEPN shares. TD Cowen began coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating on the stock. Cantor Fitzgerald began coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 target price for the company. JPMorgan Chase & Co. began coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. Finally, Wells Fargo & Company began coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price for the company.

Septerna Price Performance

The firm has a 50-day moving average price of $21.35.

Institutional Trading of Septerna

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Bank of New York Mellon Corp acquired a new position in Septerna in the 4th quarter valued at about $872,000. New York State Common Retirement Fund acquired a new position in Septerna in the 4th quarter valued at about $32,000. Rhumbline Advisers acquired a new position in Septerna in the 4th quarter valued at about $458,000. Finally, SG Americas Securities LLC acquired a new position in Septerna in the 4th quarter valued at about $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.